Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Harald Gschaidmeier"'
Autor:
Juergen Burhenne, Michael Bucher, Frank Schweda, Frieder Kees, Harald Gschaidmeier, Gerd Mikus, Lothar Faerber
Publikováno v:
Therapeutic Drug Monitoring. 28:312-320
The aim of this study was to compare the bioavailability of cyclosporine (CyA) from the generic dispersion formulation Cicloral (CIC) with the microemulsion formulation Neoral (NEO) and the original Sandimmune (SIM) capsules after single doses of 100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9603c64befe95e81e6ccee7737dd57
https://doi.org/10.1097/01.ftd.0000211804.89440.74
https://doi.org/10.1097/01.ftd.0000211804.89440.74
Autor:
Stefan Kahl, Matthias P. A. Ebert, Barbara Nitsche, C. Hosius, Jie Chen, Christoph Röcken, Peter Malfertheiner, Harald Gschaidmeier
Publikováno v:
Cancer Letters. 233:328-337
Imatinib targets KIT and platelet-derived growth factor receptors (PDGFR) and is highly effective in the treatment of CML and GIST patients. Pancreatic cancers express KIT and PDGFRs. Therefore, 26 patients with unresectable pancreatic cancer were ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1500f6c9c8bf1d51331094db43ed2201
https://doi.org/10.1016/j.canlet.2005.03.027
https://doi.org/10.1016/j.canlet.2005.03.027
Autor:
Georg Ledderose, Andrew J. Ullmann, Georg Hess, Christoph Huber, Ulrike Haus, Thomas M. Fischer, Donald Bunjes, Barbara Wassmann, Thomas Kindler, Martin Bornhäuser, Rainer Schwerdtfeger, Harald Gschaidmeier, Wolfgang Siegert, Andreas Hochhaus, Guido Kobbe
Publikováno v:
Journal of Clinical Oncology. 23:7583-7593
Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5743076d3f486a937d884a7ed8ef22e
https://doi.org/10.1200/jco.2005.01.3110
https://doi.org/10.1200/jco.2005.01.3110
Autor:
Georg Ledderose, Urban J. Scheuring, Dieter Hoelzer, Heike Pfeifer, Donald Bunjes, Barbara Wassmann, Martin Bornhäuser, Patrick Brück, Michael B. Stadler, Matthias Stelljes, Rolf Mahlberg, Anja Binckebanck, Oliver G. Ottmann, Gesine Bug, Rainer Schwerdtfeger, Jolanta B. Perz, Harald Gschaidmeier, Nadezda Basara
Publikováno v:
Blood. 106:458-463
In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0d6cab923fb30456e190eb2ffcd8e7
https://doi.org/10.1182/blood-2004-05-1746
https://doi.org/10.1182/blood-2004-05-1746
Autor:
Thomas M. Fischer, Frank Breitenbuecher, Thomas Kindler, Andreas H. Marx, Georg Hess, Joachim Beck, Birgit Weinkauf, Christoph Huber, Matthias Theobald, Harald Gschaidmeier, Charles James Kirkpatrick, Justus Duyster, Christian Peschel
Publikováno v:
Blood. 103:3644-3654
This phase 2 pilot study was conducted to determine the efficacy and safety of imatinib mesylate in patients with c-kit–positive acute myeloid leukemia (AML) refractory to or not eligible for chemotherapy. Twenty-one patients were enrolled and rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7481bf53b3406a57c71d322ef38e6f9e
https://doi.org/10.1182/blood-2003-06-2071
https://doi.org/10.1182/blood-2003-06-2071
Autor:
Heike Pfeifer, Urban J. Scheuring, Lothar Leimer, A Käbisch, Dieter Hoelzer, Oliver G. Ottmann, Anja Binckebanck, Michael Lübbert, Harald Gschaidmeier, Barbara Wassmann
Publikováno v:
Leukemia. 17:1919-1924
Imatinib has marked antileukemic activity in advanced Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), but secondary resistance develops rapidly, reflecting the limitations of single-agent therapy. Experimental data suggest tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bca2d1d9bbdd49c9bd05c92916a2e6c
https://doi.org/10.1038/sj.leu.2403093
https://doi.org/10.1038/sj.leu.2403093
Autor:
Karl Anton Kreuzer, Philipp le Coutre, Harald Gschaidmeier, Michaela Schwarz, Il-Kang Na, Gerhard Ehninger, Joachim Lupberger, Dieter Huhn, Gökben Baskaynak, Matthias Holdhoff, Christian Schmidt, Witold Prejzner, Uwe Platzbecker
Publikováno v:
American Journal of Hematology. 73:249-255
Previous clinical trials with the tyrosine kinase inhibitor imatinib in chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) resulted in 95% of hematologic and 60% major cytogenetic remissions in patients who failed a pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::572f279360c4784151b9fe9f21b3ad5b
https://doi.org/10.1002/ajh.10364
https://doi.org/10.1002/ajh.10364
Autor:
Andrew J. Ullmann, Harald Gschaidmeier, Karin Kolbe, A. Friedrich-Freksa, Thomas Fischer, Christoph Huber, Ralf G. Meyer, Georg Hess
Publikováno v:
The Keio Journal of Medicine. 52:182-188
Here, we describe a patient diagnosed with chronic myelogenous leukemia who relapsed after matched unrelated donor SCT. The patient was treated with imatinib mesylate and donor lymphocyte infusions, and achieved a complete molecular remission. Additi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b5ee0182908e451ba0fba0883e5a3eb
https://doi.org/10.2302/kjm.52.182
https://doi.org/10.2302/kjm.52.182
Autor:
Manuel Schmidt, T. Lahaye, Stefan Wölfl, Harald Gschaidmeier, Dali Cai, Andreas Neubauer, Andreas Burchert, Thomas Berg, Cornelia Brendel, Martin Müller, Andreas Hochhaus, Rüdiger Hehlmann, Burghardt Wittig, Barbara Denecke, Larissa Odyvanova
Publikováno v:
Blood. 101:259-264
Chronic myeloid leukemia (CML) is a clonal disease of hematopoietic stem cells caused by a reciprocal translocation of the long arms of chromosomes 9 and 22. In human leukocyte antigen A*0201+ (HLA-A*0201+) individuals, response after interferon-α (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66cbc41652f997eb37e6d34e0c83d5ce
https://doi.org/10.1182/blood-2002-02-0659
https://doi.org/10.1182/blood-2002-02-0659
Autor:
Dieter Hoelzer, Urban J. Scheuring, Anja Binckebanck, Hans Martin, Stefan Klein, Oliver G. Ottmann, Heike Pfeifer, Harald Gschaidmeier, Nicola Gökbuget, Barbara Wassmann
Publikováno v:
Leukemia. 16:2358-2365
Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 consecutive, not previously transplanted pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1afcff107d768d2878e35d249185b5e8
https://doi.org/10.1038/sj.leu.2402770
https://doi.org/10.1038/sj.leu.2402770